Table 3.
Univariate |
Multivariate |
|||
---|---|---|---|---|
Odds ratio (95% CI) | p | Odds ratio (95% CI) | p | |
Excess body weight, BMI ≥ 25 kg/m2 | 3.78 (1.04–13.72) | 0.04 | 5.58 (1.30–23.96) | 0.02 |
Age, years | 0.98 (0.95–1.01) | 0.17 | 0.98 (0.94–1.02) | 0.35 |
Sex | 1.48 (0.57–3.80) | 0.42 | 1.76 (0.61–5.09) | 0.30 |
Type 2 diabetes | 0.66 (0.20–2.14) | 0.49 | 0.99 (0.21–4.77) | 0.99 |
Arterial hypertension | 0.75 (0.29–1.90) | 0.54 | 0.93 (0.21–4.10) | 0.92 |
Chronic respiratory diseaseb | 1.42 (0.27–7.55) | 0.68 | 1.68 (0.23–12.33) | 0.61 |
RAAS inhibitors | 0.76 (0.27–2.15) | 0.61 | 1.25 (0.24–6.34) | 0.79 |
Statins | 0.29 (0.04–2.31) | 0.24 | 0.14 (0.01–1.74) | 0.13 |
HCQ/AZT treatment combinationc | 0.73 (0.23–2.25) | 0.58 | 0.33 (0.08–1.35) | 0.12 |
Abbreviations: AZT = azithromycin. BMI = body mass index. HCQ = hydroxychloroquine. RAAS = renin-angiotensin-aldosterone system.
Bold value is statistically significant to p-value < 0.05.
Univariate and multivariate associations between serious events and BMI between 18.5 and 25 kg/m2 (reference), BMI ≥ 25 kg/m2, age, sex, type 2 diabetes, arterial hypertension, chronic respiratory disease, RAAS inhibitors, statins and HCQ/AZT combination.
Chronic respiratory disease: asthma, obstructive sleep apnea, chronic obstructive pulmonary disease.
HCQ/AZT: combination of hydroxychloroquine for 10 days and azithromycin for 5 days.